|
The Society of Toxicologic Pathology is pleased to announce the offering of three virtual continuing education courses in 2022. All course registrants will receive a downloadable course book prior to each webinar.
|
|
|
These programs have been approved for 4.00 hours of continuing education credit in jurisdictions that recognize RACE approval.
|
From Anticipated Immunomodulation to Safety Concern: Use of Immune Biomarkers in Preclinical Studies
Friday, August 12, 2022 |12:00 Noon–3:45 PM EDT
Co-Chairs: Caitlyn Carter, DVM, DACVP, Charles River Laboratories; and Michael Logan, DVM, PhD, DACVP, AbbVie
Biomarkers of the immune system are being applied to preclinical safety studies with increasing frequency as the availability of method and platform options continues to expand. This course will focus on the use of traditional and novel biomarkers of the immune system that are being used on preclinical safety studies. Practical considerations for their appropriate, and sometimes inappropriate use will be presented including biomarker selection, application in various preclinical settings, study design, sampling collection optimization (matrix, kinetics, timing and collection), and interpretative considerations. Method limitations, pitfalls to avoid, and successful implantation strategies will also be discussed with supporting case examples. Finally, topics related to immunology biomarker components specific to emerging novel therapeutic platforms (e.g., CD3 engagement, bispecific antibodies, cell and gene therapies) will be presented.
Overview and Considerations for the Use of Biomarkers of the Immune System in Preclinical Safety Studies
Adam Aulbach, DVM, DACVP, Inotiv
Getting It Right: The Correct Assays, Matrices, and Intervals Result in a Robust Data Set. Now…How Do We Interpret Them?
Erin Vaughn, PhD, AbbVie
Possible vs. Advisable: How Do We Optimally Use (and Not Abuse) Immunology Biomarkers in a Preclinical Setting?
Rob Caldwell, PhD, AbbVie
Platform Specific Considerations: What Biomarkers Provide the Best Value for My Specialized Target/Mechanism/Modality?
Danice Wilkins, PhD, MS, Charles River Laboratories
|
Optimizing Toxicologic Pathology Data: Fundamental Concepts and Recommended Practices
— Friday, August 26, 2022
Co-Chairs: Daniel J. Patrick, DVM, DACVP, DABT, Eli Lilly & Company; and Noel D. Horton, PhD, DABT, Inotiv
|
|
Toxicologic Pathology and Risk Assessment of Environmental Exposures
— Friday, September 16, 2022
Co-Chairs: Arun K. Pandiri, BVSc&AH, MS, PhD, DACVP, DABT, NIEHS/NTP; and Maria L.Z. Dagli, DVM, MS, PhD, Universidade de São Paulo
|
|
|
|
|